NDC Pharmacologic Class N0000009176 Increased Cellular Death [PE]
| NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Product Type |
|---|---|---|---|---|---|---|
| 0008-0100 | Besponsa | Inotuzumab Ozogamicin | Injection, Powder, Lyophilized, For Solution | Intravenous | Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc. | Human Prescription Drug |
| 0074-0561 | Venclexta | Venetoclax | Tablet, Film Coated | Oral | Abbvie Inc. | Human Prescription Drug |
| 0074-0566 | Venclexta | Venetoclax | Tablet, Film Coated | Oral | Abbvie Inc. | Human Prescription Drug |
| 0074-0576 | Venclexta | Venetoclax | Tablet, Film Coated | Oral | Abbvie Inc. | Human Prescription Drug |
| 50222-502 | Picato | Ingenol Mebutate | Gel | Topical | Leo Pharma Inc. | Human Prescription Drug |
| 50222-503 | Picato | Ingenol Mebutate | Gel | Topical | Leo Pharma Inc. | Human Prescription Drug |
There are 6 NDC products with the pharmacologic class Increased Cellular Death [PE].
